Orally available Factor7a inhibitor
Thierry Lavé(Roche (Switzerland)), Holger Kuehne, Michael Ståhl(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), Leo Alig(Roche (Switzerland)), H.J. Boehm, Hans Peter Wessel, Kurt Hilpert, T. Tschopp(Roche (Switzerland)), David W. Banner(Roche (Switzerland)), L. Weber, J. Ackermann
Cited by 0
Related Papers
Fluorine in Medicinal Chemistry
|ChemBioChem|2004|1.5k
Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza
|Critical Care|2009|382
Characterization of the rapamycin-sensitive phosphoproteome reveals that Sch9 is a central coordinator of protein synthesis
|Genes & Development|2009|351
Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial
|The Lancet. Gastroenterology & hepatology|2020|202
Sch9 regulates ribosome biogenesis via Stb3, Dot6 and Tod6 and the histone deacetylase complex RPD3L
|The EMBO Journal|2011|179